Who owns Arcturus Therapeutics Holdings Inc. (ARCT)? Elite investor 13F holders
2 tracked elite investors reported holding Arcturus Therapeutics Holdings Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ARCTURUS THERAPEUTICS HLDGS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2636646.00 USD | 392358.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ARCTURUS THERAPEUTICS HLDGS | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 143808.00 USD | 21400.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.